Current research aims to generate and functionally validate recombinant antibodies to cell surface receptors, growth factors or signalling molecules. These are then used to map protein ? protein interaction networks using mass spectrometry or to test the biological effects of antagonising or agonising cell surface receptors. Some of the antibodies generated in the McCafferty Lab have therapeutic potential as anti ? cancer agents. Prior to joining John McCafferty I led a team at the Wellcome Trust Sanger Institute involved in high throughput protein expression for antibody production. Methods were developed for multiplexed high yield mammalian expression, the identification of a number of protein properties that allows soluble expression in E. coli, and a way to genetically select for soluble protein fragments. Finally an array of murine immunoglobulin superfamily (IgSF) receptors has been prepared and used to discover novel receptor interactions involved in angiogenesis.